| # | Drug | Count |
|---|---|---|
| 0 | PEGVISOMANT | 70 |
| 1 | OCTREOTIDE ACETATE | 14 |
| 2 | LANREOTIDE ACETATE | 12 |
| 3 | METFORMIN | 8 |
| 4 | METFORMIN ER 500 MG | 8 |
| 5 | METFORMIN ER 750 MG | 8 |
| 6 | CABERGOLINE | 6 |
| 7 | SOMATROPIN | 6 |
| 8 | DEXLANSOPRAZOLE | 4 |
| 9 | METOPROLOL | 4 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PEGVISOMANT | 70 | 0.0170 |
| 1 | PALTUSOTINE | 1 | 0.0042 |
| 2 | LINAGLIPTIN AND METFORMIN HYDROCHLORIDE | 2 | 0.0016 |
| 3 | LANREOTIDE ACETATE | 12 | 0.0015 |
| 4 | IPTACOPAN | 1 | 0.0013 |
| 5 | CABERGOLINE | 6 | 0.0012 |
| 6 | TESAMORELIN | 2 | 0.0012 |
| 7 | PRASTERONE | 2 | 0.0007 |
| 8 | OCTREOTIDE ACETATE | 14 | 0.0005 |
| 9 | PASIREOTIDE | 1 | 0.0004 |
| # | Drug class | Count |
|---|---|---|
| 0 | Ergot Derivative [EPC] | 6 |
| 1 | Proton Pump Inhibitor [EPC] | 5 |
| 2 | Insulin Analog [EPC] | 4 |
| 3 | Corticosteroid [EPC] | 3 |
| 4 | Dipeptidyl Peptidase 4 Inhibitor [EPC] | 3 |
| 5 | Recombinant Human Growth Hormone [EPC] | 3 |
| 6 | Aldosterone Antagonist [EPC] | 2 |
| 7 | Androgen [EPC] | 2 |
| 8 | CTLA-4-directed Blocking Antibody [EPC] | 2 |
| 9 | Expectorant [EPC] | 2 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Ergot Derivative [EPC] | 6 | 0.0012 |
| 1 | Somatostatin Analog [EPC] | 1 | 0.0001 |
| 2 | Recombinant Human Growth Hormone [EPC] | 3 | 0.0001 |
| 3 | Tissue-nonspecific Alkaline Phosphatase [EPC] | 1 | 0.0001 |
| 4 | Dipeptidyl Peptidase 4 Inhibitor [EPC] | 3 | 0.0001 |
| 5 | Androgen [EPC] | 2 | 0.0001 |
| 6 | CTLA-4-directed Blocking Antibody [EPC] | 2 | 0.0000 |
| 7 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 2 | 0.0000 |
| 8 | Sodium-Glucose Cotransporter 2 Inhibitor [EPC] | 2 | 0.0000 |
| 9 | Aldosterone Antagonist [EPC] | 2 | 0.0000 |